LYN-005, a novel long-acting oral risperidone, achieved pharmacokinetic equivalence to daily immediate-release risperidone at steady-state.
Sustained therapeutic plasma concentrations were observed with weekly dosing, supporting its potential to mitigate adherence challenges in schizophrenia.
Safety profile was consistent with established risperidone use, with gastrointestinal adverse events most common and no unexpected safety signals.
The weekly oral formulation may address a critical gap for patients preferring oral therapy but struggling with daily adherence.
